Staar Surgical Valuation Multiples

Staar Surgical is valued at $1.1B as of October 2026, a 3.0x revenue multiple. In the last 12 months, Staar Surgical revenue was $316M and Staar Surgical EBITDA was $49M.

Staar Surgical Overview

About Staar Surgical

Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company offers two types of products: Implantable Collamer lenses (ICL), which are used in refractive surgery. The company generates almost all of its revenue from the sale of its ICL products. Geographically, the company generates key revenue from Foreign sales.


Founded

1982

HQ

United States

Employees

957

Website

staar.com

Financials (LTM)

Revenue: $316M
EBITDA: $49M

EV

$938M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Staar Surgical Financials

Staar Surgical reported last 12-month revenue of $316M and EBITDA of $49M.

In the same LTM period, Staar Surgical generated $236M in gross profit, $49M in EBITDA, and had net loss of ($4M).

Revenue (LTM)


Staar Surgical P&L

In the most recent fiscal year, Staar Surgical reported revenue of $239M and EBITDA of ($37M).

Staar Surgical is unprofitable as of last fiscal year, with gross margin of 76%, EBITDA margin of (16%), and net margin of (34%).

See analyst estimates for Staar Surgical
LTMLast FY202320242025202620272028
Revenue$316M$239M$322M$314M$239M
Gross Profit$236M$182M$253M$240M$182M
Gross Margin75%76%78%76%76%
EBITDA$49M($37M)$32M($8M)($78M)
EBITDA Margin16%(16%)10%(3%)(33%)
EBIT Margin(1%)(19%)9%(4%)(19%)
Net Profit($4M)($80M)$21M($20M)($80M)
Net Margin(1%)(34%)7%(6%)(34%)

Financial data powered by Morningstar, Inc.

Staar Surgical Stock Performance

Staar Surgical has current market cap of $1.1B, and enterprise value of $938M.

Market Cap Evolution


Staar Surgical's stock price is $21.61.

Staar Surgical share price decreased by 4.5% in the last 30 days, and by 16.5% in the last year.

Staar Surgical has an EPS (earnings per share) of $-1.60.

See more trading valuation data for Staar Surgical
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$938M$1.1B-3.1%-4.5%-11.3%-16.5%$-1.60

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Staar Surgical Valuation Multiples

Staar Surgical trades at 3.0x EV/Revenue multiple, and 19.1x EV/EBITDA.

See NTM and 2027E valuation multiples for Staar Surgical

EV / Revenue (LTM)


Staar Surgical Financial Valuation Multiples

As of October 23, 2026, Staar Surgical has market cap of $1.1B and EV of $938M.

Staar Surgical has a P/E ratio of (253.6x).

LTMLast FY202320242025202620272028
EV/Revenue3.0x3.9x2.9x3.0x3.9x
EV/EBITDA19.1x(25.2x)29.5x(116.2x)(12.0x)
EV/EBIT(238.8x)(20.4x)33.4x(74.4x)(20.4x)
EV/Gross Profit4.0x5.1x3.7x3.9x5.1x
P/En/m(13.5x)50.8x(53.6x)(13.5x)
EV/FCF(44.0x)(23.4x)n/m(122.3x)(23.4x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Staar Surgical Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Staar Surgical Margins & Growth Rates

Staar Surgical grew revenue by 52% but EBITDA decreased by 305% in the last fiscal year.

In the most recent fiscal year, Staar Surgical reported gross margin of 76%, EBITDA margin of (16%), and net margin of (34%).

See estimated margins and future growth rates for Staar Surgical

Staar Surgical Margins

Last FY202420252026202720282029
Gross Margin76%76%76%74%
EBITDA Margin(16%)(3%)(33%)19%
EBIT Margin(19%)(4%)(19%)5%
Net Margin(34%)(6%)(34%)4%
FCF Margin(17%)(2%)(17%)9%

Staar Surgical Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth52%(3%)(24%)40%
Gross Profit Growth50%(5%)(24%)36%
EBITDA Growth(305%)(125%)868%(180%)
EBIT Growth(176%)(145%)264%(137%)
Net Profit Growth(136%)(195%)298%(117%)
FCF Growth(320%)113%422%(171%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Staar Surgical Operational KPIs

Staar Surgical's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.

Staar Surgical's Rule of 40 is 58% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Staar Surgical's Rule of X is 118% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Staar Surgical
LTMLast FY202320242025202620272028
Rule of 4029%58%---
Bessemer Rule of X49%118%---
Revenue per Employee-$0.3M---
Opex per Employee-$0.2M---
S&M Expenses to Revenue32%43%35%37%43%
G&A Expenses to Revenue26%36%22%29%36%
R&D Expenses to Revenue13%17%13%14%17%
Opex to Revenue-95%70%80%95%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Staar Surgical Competitors

Staar Surgical competitors include Wandong Medical, PHC Holdings, Artivion, PROCEPT BioRobotics, iRadimed, CeriBell, Tandem Diabetes Care, Shinva, Arcs Co and Beta Bionics.

Most Staar Surgical public comparables operate across Medical Devices, DeepTech and HealthTech.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Wandong Medical$202M($46M)3.4x3.0x(14.8x)-
PHC Holdings$2.3B$315M1.0x0.9x7.0x6.1x
Artivion$441M$63M3.3x3.0x23.0x15.4x
PROCEPT BioRobotics$308M($98M)2.9x2.4x(9.2x)(24.2x)
iRadimed$84M$28M12.7x11.7x38.7x32.8x
CeriBell$89M($50M)10.5x8.5x(18.6x)(14.7x)
Tandem Diabetes Care$1B($186M)1.4x1.3x(7.6x)41.2x
Shinva$1.5B$127M0.6x0.6x7.0x7.1x

This data is available for Pro users. Sign up to see all Staar Surgical competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Staar Surgical

When was Staar Surgical founded?Staar Surgical was founded in 1982.
Where is Staar Surgical headquartered?Staar Surgical is headquartered in United States.
How many employees does Staar Surgical have?As of today, Staar Surgical has over 957 employees.
Who is the CEO of Staar Surgical?Staar Surgical's CEO is Warren Foust.
Is Staar Surgical publicly listed?Yes, Staar Surgical is a public company listed on Nasdaq.
What is the stock symbol of Staar Surgical?Staar Surgical trades under STAA ticker.
When did Staar Surgical go public?Staar Surgical went public in 1983.
Who are competitors of Staar Surgical?Staar Surgical main competitors include Wandong Medical, PHC Holdings, Artivion, PROCEPT BioRobotics, iRadimed, CeriBell, Tandem Diabetes Care, Shinva, Arcs Co, Beta Bionics.
What is the current market cap of Staar Surgical?Staar Surgical's current market cap is $1.1B.
What is the current revenue of Staar Surgical?Staar Surgical's last 12 months revenue is $316M.
What is the current revenue growth of Staar Surgical?Staar Surgical revenue growth (NTM/LTM) is 13%.
What is the current EV/Revenue multiple of Staar Surgical?Current revenue multiple of Staar Surgical is 3.0x.
What is the current EBITDA of Staar Surgical?Staar Surgical's last 12 months EBITDA is $49M.
What is Staar Surgical's EBITDA margin?Staar Surgical's last 12 months EBITDA margin is 16%.
What is the current EV/EBITDA multiple of Staar Surgical?Current EBITDA multiple of Staar Surgical is 19.1x.
What is the current FCF of Staar Surgical?Staar Surgical's last 12 months FCF is ($21M).
What is Staar Surgical's FCF margin?Staar Surgical's last 12 months FCF margin is (7%).
What is the current EV/FCF multiple of Staar Surgical?Current FCF multiple of Staar Surgical is (44.0x).
How many companies Staar Surgical has acquired to date?Staar Surgical hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Staar Surgical has invested to date?Staar Surgical hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Staar Surgical

Lists including Staar Surgical

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial